A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
* Reuters is not responsible for the content in this press release.
For best results when printing this announcement, please click on the link below: http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130221:nPn2214815 NEW YORK, February 21, 2013 /PRNewswire/ -- Today, National Traders Association announced new research reports highlighting Novogen Limited (NASDAQ: NVGN), Sanofi SA (NYSE: SNY), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Amgen, Inc. (NASDAQ: AMGN) and Gilead Sciences, Inc. (NASDAQ: GILD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Novogen Limited Research Report Novogen's shares jumped 200 percent after a study revealed that its anti-ovarian cancer drug was not only effective against ovarian cancer cells, it was also effective against ovarian cancer stem cells. Cancer stem cells have been found in a range of cancers including ovarian, brain and leukemia, and are resistant to radiotherapy and typical anti-cancer drugs. They are also normally responsible for cancer recurrence, the main cause of death among patients. With this new discovery, Novogen hopes that its new drug, the CS-6 and the super benzopyran family of drugs to which it belongs, would eventually become a comprehensive cancer treatment. Many investors have already jumped to buy shares, expecting that CS-6 would become the catalyst for Novogen's long-term growth. The Full Research Report on Novogen Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.NationalTradersAssociation.org/r/full_research_report/0f8c_NVGN] -- Sanofi SA Research Report Sanofi's shares rallied after the U.S. Food and Drug Administration (FDA) accepted lixisenatide for review. Lixisenatide is the first once-daily treatment of adults with type 2 diabetes mellitus. Lixisenatide has also been approved for the European Union, and will be launched as Lyxumia later in the first quarter. This follows regulatory approvals for Kynamro, Zaltrap, and Aubagio. Additionally, Sanofi's subsidiary Genzyme also announced positive new data from phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, an investigational oral therapy for Gaucher disease type 1. With a string of approvals to boast of, many believe that the pharmaceutical giant will be able to generate strong revenue in the upcoming quarters. Warren Buffett is among Sanofi's shareholders, along with Abrams Capital. The Full Research Report on Sanofi SA - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.NationalTradersAssociation.org/r/full_research_report/63b2_SNY] -- ISIS Pharmaceuticals, Inc. Research Report ISIS and Genzyme have announced the US Food and Drug Administration (FDA) approval of their new product, the KYNAMROTM injection. The injection reduces low density liproprotein-cholesterol, apoliprotein B, total cholesterol, and high density lipoprotein-cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare inherited condition which makes the body unable to remove LDL cholesterol. In the United States, HoFH occurs in one in a million individuals, and for patients with this condition, heart attacks, and death can occur before age 30. Analysts expect that the product will earn $400 million in peak sales, with Isis getting 30 percent to 50 percent of the profit, depending on total sales. Sanofi, the pharma giant that owns Genzyme, will be helping to market this product. Moreover, ISIS recently earned $7.5 million payment from GlaxoSmithKline for the initiation of the Phase2/3 clinical study of ISIS-TTR, a treatment for transthyretin (TTR) amyloidosis, a genetic disease characterized by the dysfunction of peripheral nerve or heart tissues. The Full Research Report on ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.NationalTradersAssociation.org/r/full_research_report/555f_ISIS] -- Amgen, Inc. Research Report Amgen reported that its late-stage pipeline is advancing, with two pivotal phase 3 trials due this year, five in 2014, and one in 2016. Analysts have been praising Amgen for its promising pipeline and its solid long-term strategy, with researchers at the Jefferies Group reiterating their buy rating on the shares of the company. The world's largest biotechnology company notes six biosimilars as its next opportunity for growth, hoping that these products would generate a combined peak of $41 billion in global sales. It is also creating a new manufacturing process that includes launching new manufacturing technologies that aim to reduce the capital needed to produce products. It is also planning to expand globally as it launches products in Japan by 2016. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.NationalTradersAssociation.org/r/full_research_report/7b3e_AMGN] -- Gilead Sciences, Inc. Research Report Gilead announced results from the Phase 3 FUSION study of its Hepatitis C drug, Sofosbuvir. The study concluded that the drug is effective in treating Hepatitis C patients who could not be cured by existing medications that contained pegylated interferon. Interferon is an ingredient loaded with side effects that often led to patients discontinuing therapy. With this, Gilead is on track to file regulatory applications for the drug in the United States and Europe in the second quarter. The results mark a remarkable run for the company after taking less than 16 months to finish its Phase III phase. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.NationalTradersAssociation.org/r/full_research_report/6e69_GILD] -- Consider National Traders Association Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks. Contact: Demi Lapierre Email: press@NationalTradersAssociation.org Main: +1(702)212-4493 SOURCE National Traders Association